Screener
BridgeBio Pharma BBIO Interest Expense
Interest Expense at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Loss from operations | (105,956) | (104,372) |
| Other income (expense), net: | ||
| Interest income | 6,246 | 5,385 |
| Interest expense | (12,942) | (18,121) |
| Noncash interest expense on deferred royalty obligations (1) | (39,873) | (24,020) |
| Loss on extinguishment of debt | — | (21,155) |
| Net loss from equity method investments | (18,283) | (15,556) |
| Other income, net | 4,253 | 8,231 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's interest expense?
- BridgeBio Pharma (BBIO) reported interest expense of $12.94M in Q1 2026.
- How has BridgeBio Pharma's interest expense changed year-over-year?
- BridgeBio Pharma's interest expense decreased by 28.6% year-over-year, from $18.12M to $12.94M.
- What is the long-term trend for BridgeBio Pharma's interest expense?
- Over 4 years (2021 to 2025), BridgeBio Pharma's interest expense has grown at a 14.0% compound annual growth rate (CAGR), from $46.78M to $79.13M.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.
Ask your AI about BridgeBio Pharma's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude